Table 1 Properties of bispecific antibodies for multiple myeloma
Author | NCT No. | Agents | Ig type | Structural format | Target | Phase | References |
|---|---|---|---|---|---|---|---|
Firestone R | N/A | Teclistamab | IgG4 | 1 + 1 symmetric | BCMA/CD3 | post-marketing revaluation | [4] |
Mohty M | NCT 04649359 | Elranatamab | IgG2a | 1 + 1 symmetric | BCMA/CD3 | II | [5] |
Lee HC | NCT03761108 | Linvoseltamab | IgG4κ | 1 + 1 symmetric | BCMA/CD3 | I/II | [6] |
Sun MY | NCT 04984434 | F182112 | -- | -- | BCMA/CD3 | I | [7] |
Morillo D | NCT 03399799 | Talquetamab | IgG4PAA | 1 + 1 symmetric | GPRC5D/CD3 | I | [8] |
Schinke CD | NCT 04634552 | Talquetamab | IgG4PAA | 1 + 1 symmetric | GPRC5D/CD3 | I/II | [8] |
Bachier CR | NCT05535244 | Cevostamab | IgG1 | 1 + 1 symmetric | FcRH5/CD3 | I/II | [11] |